Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: Results from RA-BEYOND

Rheumatoid Arthritis

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

Clin Rheumatol.

van der Heijde D, Durez P, Schett G, Naredo E, Østergaard M, Meszaros G, De Leonardis F, de la Torre I, López-Romero P, Schlichting D, Nantz E, Fleischmann R

doi: 10.1007/s10067-018-4221-0.

Rheumatoid Arthritis

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

Ann Rheum Dis.

Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T

doi: 10.1136/annrheumdis-

Rheumatoid Arthritis

Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis

Arthritis Res Ther.

Rydell E, Forslind K, Nilsson JÅ, Jacobsson LTH, Turesson C

doi: 10.1186/s13075-018-1575-2.

Rheumatoid Arthritis

The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: Results from the Norfolk Arthritis Register

Arthritis Rheumatol.

Gwinnutt JM, Symmons DP, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SM

doi: 10.1002/art.40090.

Rheumatoid Arthritis

Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN

Arthritis Res Ther.

López-Romero P, Martinez-Gamboa L, Bang H, de la Torre I, Holzkämper T, Feist E

doi: 10.1186/s13075-020-02284-y.

Rheumatoid Arthritis

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

Ann Rheum Dis.

Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A

doi: 10.1136/annrheumdis-2018-213502.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Patient global assessment and radiographic progression in early arthritis: 3-year results from the ESPOIR cohort

Arthritis Care Res (Hoboken).

Ferreira RJO, Fautrel B, Saraux A, Gaujoux-Viala C, Rat AC, Guillemin F, da Silva JAP, Dougados M, Gossec L

doi: 10.1002/acr.24237.

Rheumatoid Arthritis

Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial

JAMA.

Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg B, Hetland ML, Ørnbjerg LM, Glinatsi D, Møller J, Boesen M, Christensen R, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge EM, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Nielsen SM, Bliddal H, Krogh NS, Ellingsen T, Nielsen AH, Balding L, Jurik AG, Thomsen HS, Østergaard M

doi: 10.1001/jama.2018.21362.

Rheumatoid Arthritis

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

J Rheumatol.

Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL

doi: 10.3899/jrheum.171361.

Related content

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis

The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: Results from the Norfolk Arthritis Register

Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

Patient global assessment and radiographic progression in early arthritis: 3-year results from the ESPOIR cohort

Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment